JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)

Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies

Author(s): Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, Wanxia PU
Affiliation(s): Key Laboratory of New Animal Drug Project, Gansu Province/Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs/Lanzhou Institute of Husbandry and Pharmaceutical Sciences of the Chinese Academy of Agricultural Sciences, Lanzhou 730050, China; more
Corresponding email(s): puwanxia@caas.cn, kchoi@cbu.ac.kr
Key Words: Poly(ADP-ribose) polymerase (PARP); PARP inhibitor (PARPi); Cancer; PARPi resistance; PARPi modulation; Cancer alternative therapies

Share this article to： More <<< Previous Paper \|Next Paper >>>

Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, Wanxia PU. Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2400146

@article{title="Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies",
author="Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, Wanxia PU",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2400146"
}

%0 Journal Article
%T Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies
%A Muhammad SHOAIB
%A Zeeshan Ahmad BHUTTA
%A Ahsan JAVED
%A Muhammad Nabeel AMJAD
%A Wenzhu LI
%A Kyung-Chul CHOI
%A Wanxia PU
%J Journal of Zhejiang University SCIENCE B
%P
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2400146"

TY - JOUR
T1 - Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies
A1 - Muhammad SHOAIB
A1 - Zeeshan Ahmad BHUTTA
A1 - Ahsan JAVED
A1 - Muhammad Nabeel AMJAD
A1 - Wenzhu LI
A1 - Kyung-Chul CHOI
A1 - Wanxia PU
J0 - Journal of Zhejiang University Science B
SP -
EP -
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2400146"

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract: Poly(ADP-ribose) polymerase (PARP) is a family of proteins that play a crucial role in diverse cellular processes, including DNA repair, cell death, and changes in chromatin structure. PARP inhibitors (PARPi) have been recognised as notable agents in the realm of anticancer therapeutics owing to their capacity to specifically impact DNA repair pathways, thereby inducing targeted death of cancerous cells, particularly in cancers with homologous recombination deficiencies (HRD). These inhibitors have been approved for the treatment of several cancers, such as ovarian, breast, and pancreatic cancers. Despite their promising therapeutic attributes, developing resistance to PARPi presents a formidable obstacle, curtailing their overall efficacy. This article presents a comprehensive description of the potential mechanisms related to PARPi resistance, an in-depth study of potential strategies to overcome resistance, and an assessment of the therapeutic potential of the PARPi in combination with alternative therapies.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

Open peer comments: Debate/Discuss/Question/Opinion

<1>

- Go to

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference